Plain-English translation of NCT05995028 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called 4SCAR7U, which uses immune cells that have been genetically engineered in a laboratory to recognize and attack blood cancer cells. The cells are made in advance and stored, so they can be given to patients quickly without waiting for custom preparation. Researchers want to see if this medication is safe and effective for people with certain types of blood cancers, including T-cell leukemia, lymphoma, and myeloid leukemia.
Many patients with these aggressive blood cancers don't respond well to standard treatments or experience early relapse. This medication is designed to target a specific marker found on cancer cells, offering a potentially more effective treatment option for people who need it most.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive an infusion of the engineered immune cells (4SCAR7U). The cells are created in advance specifically to target your cancer type, so treatment can begin promptly. You would be monitored closely throughout the study to assess how well the treatment works and to watch for any side effects, with the goal of understanding whether this new approach is safe and effective for patients with your condition.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
China